Wells Fargo analyst Tiago Fauth raised the firm’s price target on BridgeBio (BBIO) to $88 from $84 and keeps an Overweight rating on the shares. The firm notes Attruby revenues posted a solid Q4 beat, and Wells is raising its FY26 estimates by up 10%. The firm conservatively models some seasonality for Q1 but consistent quarter-over-quarter growth Q2-Q4 in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Showcases Attruby Growth and Pipeline Progress
- BridgeBio sees Q4 Attruby revenue $146M
- BridgeBio price target raised to $86 from $80 at Truist
- BridgeBio initiated with an Overweight at Morgan Stanley
- BridgeBio Pharma: Emerging Rare Disease Leader With Robust Growth Outlook and Discounted Valuation Supporting Buy Rating